These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 28710334)

  • 1. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas.
    Du W; Seah I; Bougazzoul O; Choi G; Meeth K; Bosenberg MW; Wakimoto H; Fisher D; Shah K
    Proc Natl Acad Sci U S A; 2017 Jul; 114(30):E6157-E6165. PubMed ID: 28710334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
    Duebgen M; Martinez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K
    J Natl Cancer Inst; 2014 Jun; 106(6):dju090. PubMed ID: 24838834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
    J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas.
    Kanaya N; Kitamura Y; Lopez Vazquez M; Franco A; Chen KS; van Schaik TA; Farzani TA; Borges P; Ichinose T; Seddiq W; Kuroda S; Boland G; Jahan N; Fisher D; Wakimoto H; Shah K
    Sci Transl Med; 2023 May; 15(698):eade8732. PubMed ID: 37256936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
    Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
    Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
    Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
    [No Abstract]   [Full Text] [Related]  

  • 8. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
    Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J
    Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses.
    Alayo QA; Ito H; Passaro C; Zdioruk M; Mahmoud AB; Grauwet K; Zhang X; Lawler SE; Reardon DA; Goins WF; Fernandez S; Chiocca EA; Nakashima H
    Sci Rep; 2020 Mar; 10(1):5095. PubMed ID: 32198420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.
    Leoni V; Gatta V; Palladini A; Nicoletti G; Ranieri D; Dall'Ora M; Grosso V; Rossi M; Alviano F; Bonsi L; Nanni P; Lollini PL; Campadelli-Fiume G
    Oncotarget; 2015 Oct; 6(33):34774-87. PubMed ID: 26430966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
    Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
    Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.
    Castelo-Branco P; Passer BJ; Buhrman JS; Antoszczyk S; Marinelli M; Zaupa C; Rabkin SD; Martuza RL
    Gene Ther; 2010 Jun; 17(6):805-10. PubMed ID: 20220784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma.
    Reale A; Gatta A; Shaik AKB; Shallak M; Chiaravalli AM; Cerati M; Zaccaria M; La Rosa S; Calistri A; Accolla RS; Forlani G
    J Transl Med; 2024 Sep; 22(1):862. PubMed ID: 39334370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syngeneic mesenchymal stem cells loaded with telomerase-dependent oncolytic adenoviruses enhance anti-metastatic efficacy.
    Yang ML; Hu CY; Lee YC; Chang CC; Chen YC; Lee PR; Su BH; Chen PC; Shiau AL; Shieh GS; Wu CL; Wu P
    Stem Cells Transl Med; 2024 Aug; 13(8):738-749. PubMed ID: 38864209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
    Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
    Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy.
    Noh MH; Kang JM; Miller AA; Nguyen G; Huang M; Shim JS; Bueso-Perez AJ; Murphy SA; Rivera-Caraballo KA; Otani Y; Kim E; Yoo SH; Yan Y; Banasavadi-Siddegowda Y; Nakashima H; Chiocca EA; Kaur B; Zhao Z; Lee TJ; Yoo JY
    Neuro Oncol; 2024 Sep; 26(9):1602-1616. PubMed ID: 38853689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
    Yoo JY; Pradarelli J; Haseley A; Wojton J; Kaka A; Bratasz A; Alvarez-Breckenridge CA; Yu JG; Powell K; Mazar AP; Teknos TN; Chiocca EA; Glorioso JC; Old M; Kaur B
    Clin Cancer Res; 2012 Sep; 18(18):4931-41. PubMed ID: 22753591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
    Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
    Jahan N; Lee JM; Shah K; Wakimoto H
    Int J Cancer; 2017 Oct; 141(8):1671-1681. PubMed ID: 28567859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.
    Chastkofsky MI; Pituch KC; Katagi H; Zannikou M; Ilut L; Xiao T; Han Y; Sonabend AM; Curiel DT; Bonner ER; Nazarian J; Horbinski CM; James CD; Saratsis AM; Hashizume R; Lesniak MS; Balyasnikova IV
    Clin Cancer Res; 2021 Mar; 27(6):1766-1777. PubMed ID: 33272983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.